Key result
RCT tests valsartan plus ACE inhibitor versus monotherapy for GFR changes in chronic renal insufficiency.
Why the study?
In Japan, the exact incidence of contrast-induced nephropathy after coronary angiography in patients with chronic renal insufficiency remains unknown, and pharmacological interventions to benefit patients undergoing CABG or PCI have not been fully investigated.
RCT (n=500)
Open-label
Dynamic allocation method (modified minimization method) stratified by gender, age, systolic blood pressure, and diabetes
No
Answers are grounded in this paper and cite their sources.
BACKGROUND: Despite an increase in the frequency of coronary angiography (CAG) in Japan, the exact incidence of contrast-induced nephropathy (CIN) remains unknown in the Japanese population, especially in patients with chronic renal insufficiency. In addition, the nature of pharmacological interventions that would benefit the patients before or after procedures such as coronary bypass graft (CABG) and percutaneous coronary intervention (PCI) has not been fully investigated. METHODS: In the trial 500 patients with renal insufficiency (defined as a glomerular filtration rate (GFR) of between 89 and 30 ml . min(-1) . (1.73 m(-2)) following CAG will be randomly assigned to receive either valsartan, an angiotensin receptor blocker or angiotensin converting enzyme (ACE) inhibitor plus valsartan.1 The primary end-point is a change in the GFR of patients, which will be followed up for 3 years, including following CABG surgery or PCI. The incidence of cardiac events as well as the adverse effects of pharmacological intervention will be evaluated. In addition, the incidence of renal artery stenosis at the time of CAG will be reported also; however, the patients with renal artery stenosis will be excluded from the present study. CONCLUSION: The present study will provide data on: 1) the exact incidence and course of renal function of CIN after CAG; and 2) the comparative therapeutic benefit of pharmacological intervention with valsartan alone or with valsartan and an ACE inhibitor in combination in patients with coexisting coronary artery diseases and chronic renal insufficiency, regardless of whether they receive CABG or PCI. In addition to these studies, an estimate of the incidence of renal artery stenosis in these patients will be demonstrated.
No takes yet. Share an insight, caveat, or question.
Ikeda et al. (2006) conducted an RCT in Coexisting coronary artery disease and chronic renal insufficiency undergoing coronary angiography (n=500). Valsartan plus an ACE inhibitor (e.g., enalapril) vs. Valsartan monotherapy titrated to 40 mg daily was evaluated on Change in glomerular filtration rate (GFR) evaluated by the Cockcroft-Gault equation over 3 years. Valsartan plus an ACE inhibitor versus valsartan monotherapy will be evaluated over 3 years for changes in GFR in 500 patients with chronic renal insufficiency undergoing angiography.
Synapse has enriched 10 related papers. Consider them for comparative context: